InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（1 笔）
内部人交易记录
高级管理人员已披露买入
0
已披露卖出
1
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
无可用的信号评分。
Explore the complete record of transactions filed by Wiley Matthew T., Directeur Commercial. Officer active across 3 companies, notably VYNE Therapeutics Inc.. Cumulatively, 10 reports have been logged. Split: 0 buy · 1 sell. Activity tracked since 30 June 2021. The latest transaction was filed on 14 September 2026 (Attribution). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Wiley Matthew T.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报10 总计
125,000 股0Common SharesSEC:0001193125-26-389890:0
62,500 股0Common SharesSEC:0001193125-26-345836:0
2,867 股Common SharesSEC:0001193125-26-285558:0
62,500 股Common SharesSEC:0001193125-26-276881:0
115,000 股0Common SharesSEC:0001193125-26-039598:0
21,250 股Common StockSEC:0001104659-24-106064:0
750 股Common StockSEC:0001104659-24-100746:0
750 股Common StockSEC:0001104659-24-073003:0
3,000 股Common StockSEC:0001104659-24-044859:0
5,151 股@ US$3.51100.0% 占其流量Common StockSEC:0001209191-21-044980:0
10 条申报中的 10 条
About Wiley Matthew T.
Wiley Matthew T. is Chief Commercial Officer. He is linked to Definium Therapeutics, Inc., BioXcel Therapeutics, Inc. and VYNE Therapeutics Inc., and his record includes 9 filings in total. Among the recent filings tracked, the period runs from 2021-07-02 to 2026-08-12, with buy and sell amounts shown as EUR 0, and the modal transaction nature is Attribution.
